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1. INTRODUCTION 
Analytical methods development and validation play important roles in the 
discovery, development, and manufacture of pharmaceuticals. The current good 
manufacturing practice (CGMP) and Food Drug Administration (FDA) Guidelines 
insist for adoption of sound methods of analysis with greater sensitivity and 
reproducibility. Development of a method of analysis is usually based  on prior art 
(or) existing literature, using the same (or) quite similar instrumentation .It is rare 
today that an HPLC-based method is developed that does not in same way relate (or) 
compare to existing, literature based approaches. Today HPLC (High performance 
liquid chromatography) is the method of choice used by the pharmaceutical industry 
to assay the intact drug and degradation products. The appropriate selection and 
chromatographic conditions ensure that the HPLC method will have the desired 
specificity. UV spectroscopy is also a simple analytical tool widely used for routine 
assay of drugs. Hence for the assay of the selected drugs HPLC and UV spectroscopy 
has been chosen for these proposed methods11. 
The developed chromatographic methods further validated as per ICH or 
USFDA guidelines for all the critical parameters. To access the precision and to 
evaluate the results of analysis the analyst must use statistical methods. These 
methods include confidence limit, regression analysis to establish calibration curves. 
In each analysis the critical response parameters must be optimized and recognized if 
possible. 
Pharmaceutical Analysis plays a major role today, and it can be considered as 
an interdisciplinary subject. Pharmaceutical analysis derives its principles from 
various branches like chemistry, physics. And microbiology etc. pharmaceutical 
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Analytical techniques are applied mainly in two areas, quantitative analysis and 
qualitative analysis, although there are several other applications. 
Drugs and pharmaceuticals are chemicals or like substances, which or of 
organic inorganic or other origin. Whatever may be the origin, we some property of 
the medicinal agent to measure them quantitatively or qualitatively. 
In recent years, several analytical techniques have been evolved that combine 
two or more methods into one called “hyphenated” technique eg: GC/MS, LC/MS etc. 
The complete Analysis of a substance consists of four main steps. 
The concept of analytical chemistry lies in the simple, precise and accurate 
measurements. These determinations require highly sophisticated instruments and 
methods like mass spectroscopy, gas chromatography, HPTLC, HPLC, etc. HPLC 
method is sensitive, accurate, precise and desirable for routine estimation of drugs in 
formulations.  
Thereby it is advantageous than volumetric methods. Many HPLC methods 
has been developed and validated for the quantitative determination of various 
marketed drugs. 
Analytical method development and validation places an important role in 
drug discovery and manufacture of pharmaceuticals. These methods are used to 
ensure the identity, purity, potency and performance of drug products majority of 
analytical development effort goes into validating a stability indicating method. So it 
is a quantitative analytical method based on the structure and chemical properties of 
each active ingredient of the drug formulation. 
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Most of the drugs can be analyzed by HPLC method because of several 
advantages like rapidity, specificity, accuracy, precision, reproducibility, ease of 
automation and eliminates tedious extraction and isolation procedures. 
On the literature survey, it was found that most of the analytical method 
available for the above mentioned drug is applicable for quantification in plasma 
samples, the most widely used method being liquid chromatography-mass 
chromatography. So it is felt that there is a need to develop accurate, precise 
analytical methods for the estimation of the drug in solid dosage formulation1. 
Newer analytical methods are developed for these drugs or drug combinations of 
the below reasons: 
• There may not be suitable method for a particular analyte in the specific 
matrix. 
• Existing method may be too error prone or unreliable (have poor accuracy and 
precision). 
• Existing method may be expensive, time consuming, energy intensive and 
may not be provide sensitive or analyte selectivity, and not easy for 
automation. 
• Newer instrumentation and techniques may have evolved that provide 
opportunities for improved methods. 
• There may be need for an alternate method to confirm, for legal and scientific 
reasons. 
The newly developed analytical methods having their importance in different 
fields that include, research and development centre (R&D), Quality control 
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department (QC). Approved testing laboratories, chemical Analysis laboratories etc. 
For analysis of these drugs different analytical methods are routinely being used4. 
The analytical methods are classified as classical and instrumental. These 
methods signal measured in those methods was mentioned in following table. 
Table 1 : Classification of analytical method 
Measurement signal Analytical method 
Chromatographic techniques 
Electrical Gas chromatography (Thermal conductivity detector) 
Increase in electrical 
current 
Gas chromatography (Flame ionization detector) 
Decrease in electrical 
current 
Gas chromatography (Flame capture detector) 
Electromagnetic 
radiation absorbed 
Liquid chromatography (Ultraviolet Light detector, Diode array 
detector) 
Electrical Ion  chromatography 
Spectrophotometric method 
Emission radiation Emission spectroscopy (X-ray, UV, Visible), Fluorescence and 
phosphorescence (X-ray, UV, Visible),radiochemistry. 
Absorption of 
radiation 
Spectrophotometry (X-ray, UV, Visible, IR) NMR and Electron 
spin resonance spectroscopy. 
Scattering of radiation Turbidimetry, Nephelometry, Raman spectroscopy 
Refraction of radiation Refractometry, Interferometry 
Diffraction of Light X-ray and Electron diffraction 
Rotation of radiation Polarimetry, Optical rotatory dispersion 
Mass to charge ratio Mass spectroscopy 
Electro chemical techniques 
Electrical potential Potentiometry 
Electrical current Polarography, Amperometry 
Electrical resistance Conductometry 
Miscellaneous techniques 
Rate of reaction Kinetic method 
Thermal properties DTA.DSC 
Classical methods 
Mass Gravimetric Analysis 
Volume Volumetric Analysis2 
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2. CHROMATOGRAPHY 
Techniques related to chromatography have been used for centuries to separate 
materials such as dyes extracted from plants. Russian botanist Tswett is credited with 
the discovery of chromatography. In 1903 he succeeded in separating leaf pigments 
using a solid polar stationary phase, It was not until 1930s that this technique was 
followed by Kuhn and Lederer as well as Reichstein and van Euw for the separation 
of natural products. Martin and synge were awarded the Nobile prize for their work in 
1941 in which they described liquid-liquid chromatography. Martin and synge applied 
the concept of theoretical plates as a measure of chromatographic efficiency. The term 
“chromatography” (Color-writing derived from the Greek for Color-chroma and 
Write-Graphing)18. 
CHROMATOGRAPHY IN THE PHARMACEUTICAL WORLD 
In the modern pharmaceutical industry, chromatography is the major and 
integral analytical    tool applied in all stages of drug discovery, development, and 
production. The development of new chemical entities (NCEs) is comprised of two 
major activities. Drug discovery and development. The goal of the drug discovered is 
to investigate a plethora of compounds employing fast screening approaches, leading 
to generation of lead compounds and then narrowing the selection through targeted 
synthesis and selective screening (lead optimization). The main functions of drug 
development are to completely characterize candidate compounds by performing drug 
metabolism, preclinical and clinical screening, and clinical trails. Throughout this 
drug  discovery and development paradigm, rugged analytical HPLC separation 
methods are developed, at each phase of development to analyses of a myriad of 
samples are performed to adequately control and monitor the quality of the 
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prospective drug candidates, excipients, and final products. Effective and fast method 
development is of paramount importance throughout. This drug development life 
cycle. This requires a thorough understanding of HPLC principles and theory which 
have solid foundation for appreciating the many variables that are optimized during 
fast and effective HPLC method development and optimization3. 
3. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
3.1 Brief Historical prospective of chromatography: 
The historical development of liquid chromatography has been extensively 
reviewed and can be traced as far back as they early 1900, where the Russian botanist 
Zwett used a variant of liquid chromatography to separate some colored plant 
substances. The focus was on modern development in HPLC, a term that was coined 
in late 1960s with the advent of more sophisticated instrumentation, better engineered 
separation columns, and reliable and highly efficient stationary phases and packaging 
materials. 
These technological advances have been, In part, fuelled, by the need to 
separate an increasingly large variety of differing compounds classes encountered as 
API s, e.g. Antibiotic, sulphonamides  nucleosides, fat soluble vitamins neutral and 
non polar compounds. Additional challenges include developing faster and more 
consistent HPLC methods requiring higher flow rates, while maintaining peak shape, 
peak symmetry and efficiencies. Another important analytical challenge is the desire 
to detect and accurately quantify low levels of impurities at level present in API 
materials. 
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High-pressure liquid chromatography quickly improved with the development 
of column packing materials. Additional convenience of on-line detectors became 
rapidly a powerful separation technique and is today called as High-performance 
liquid chromatography (HPLC) 
 One of the early problems with liquid state chromatography was the slow rate at 
which analysis took place. Early methods use gravity feed, and it was not 
uncommon diffusion and soon. 
 This problem was largely overcome by the advent High-performance liquid 
Chromatography (HPLC). In this system the pressure is applied to the column 
forcing the mobile phase through at much higher rate. 
 For an analysis to take several days to complete. This led not only to great delay 
but also the excessive time on the column and thus inevitably led to loss of 
resolution by 
Table: 2. Different types of chromatographic techniques 
S. No. Basic principle involved Type of chromatography 
1 Techniques by 
chromatographic 
bed shape 
Column chromatography 
Paper chromatography 
Thin layer chromatography 
2 Techniques by physical 
state of mobile phase 
Gas chromatography 
Liquid chromatography 
3 Affinity chromatography Super critical fluid chromatography 
4 Techniques by separation 
mechanism 
Ion Exchange chromatography 
Size Exclusion chromatography 
5 Special techniques Reversed phase chromatography 
Two-dimensional chromatography 
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HPLC 
In High-performance liquid chromatography, mobile as well as the stationary 
phase compete for the distribution of the sample components. In case of HPLC, 
separation is based on adsorption and partition. Adsorption chromatography employs 
high-surface area particles that adsorb the solute molecules. Usually a polar solid such 
as silica gel, alumina or porous glass beads and a non-polar mobile phase such as 
heptanes, octane or chloroform are used in adsorption chromatography. 
In partition chromatography, the solid support is coated with a liquid 
stationary phase. The relative distribution of solutes between the two liquid phases 
determines the separation. The stationary phase can either polar or non-polar. If the 
stationary phase is non-polar, it is called normal phase partition chromatography. If 
the opposite case holds, it is called reversed-phase partition chromatography. In 
normal phase mode, the polar molecule partition preferentially in to the stationary 
phase and are retained longer than non-polar compounds. In reverse phase partition 
chromatography, the opposite behavior is observed8. 
3.2 TYPES OF HPLC TECHNIQUES: 
Based on modes of chromatography: 
• Normal phase chromatography 
• Reverse phase chromatography 
Based on principle of separation: 
 Adsorption chromatography 
 Ion exchange chromatography 
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 Size exclusion chromatography 
 Affinity chromatography 
Based on elution technique: 
o Isocratic separation 
o Gradient separation 
Based on the scale of operation: 
 Analytical HPLC 
 Preparative HPLC 
Ion Exchange chromatography: Due to differences in the affinity of ions for the in 
exchange.  
Size Exclusion chromatography: Due to differences in molecular weight and size of 
the molecules to be separated. 
Affinity chromatography: Separation is based on a chemical interaction specific 
tothe target species. The more popular revered phase mode uses a buffer and an added 
counter-ion of opposite charge to the sample with separation being influenced by pH, 
ionic strength, temperature, concentration of and type of organic co-solvents(s). 
Chiral chromatography: Separation of the enantiomers can be achieved on chiral 
stationary phases by the formation of diastereomers. 
Analytical HPLC: only analysis of the samples is done. Recovery of the samples                     
for reusing is normally not done6. 
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3.3 MOST COMMONLY USED METHODS IN HPLC 
Normal phase chromatography: 
For a polar stationary bed like silica we need to choose a relatively non-polar 
Mobile phase. This mode of operation is termed as Normal phase chromatography. 
Here the least polar component elutes first, and increasing the mobile phase polarity 
leads to decrease in elution time. Non-polar solvents like pentane, Hexane, isooctane, 
cyclohexane, etc. are more popular. It is mainly used for separation of nonionic, non-
polar to medium polar substances. 
Reverse phase chromatography: 
In 1960s, chromatographers started modifying the polar nature of the silanol 
group by chemically reacting silicon with organic silanes. The object was to make 
silica less polar or non-polar so that polar solvents can be used to separate water-
soluble polar compounds. Since the ionic nature of the reverted, the chromatographic 
separation carried out with such silica is referred to as Reverse- phase 
chromatography.  Here the most post components elutes first. Increasing mobile phase 
polarity leads to decrease In elution time. common solvents used in this mode include 
Methanol /Acetonitrile /Isopropanal etc. Mostly used for separation of ionic and polar 
substances. The parameters that govern the retention in reversed phase system are the 
following: 
a. The chemical nature of the stationary phase surface. 
b. The type of solvents that compose the mobile phase. 
c. pH and ionic strength of the mobile phase. 
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Isocratic elution:  A separation in which the mobile phase composition remains 
constant throughout the procedure is termed isocratic (meaning constant 
composition). 
Gradient elution: The mobile phase composition does not have to remain constant. A 
separation in which the mobile phase composition is changed during the separation 
process is described as a gradient elution10. 
3.4 INSTRUMENTATION OF HPLC: 
The mobile phase components HPLC instrument and their working functions are 
described below. 
• Mobile phase and reservoir 
• Solvent degassing system 
• Pump 
• Injector 
• Colum 
• Detector 
• Data system 
 
Figure1: Schematic diagram of HPLC instrumentation 
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I.MOBILE PHASE AND RESERVIOR: 
 The most common type of solvent reservoir is a glass bottle. The mobile phase 
is pumped under pressure from one of several reservoirs and flows through the 
column at a constant rate. With micro particulate packing, there is a high-pressure 
drop across a chromatography column. Mobile phase used for HPLC are typically 
mixtures of organic solvents and water or aqueous buffers. The following points 
should also be considered when choosing amobile phase: 
• The essential to establish that the drug is stable in the mobile phase for at least the 
duration of the analysis. 
• Excessive salt concentrations should be avoided. High salt concentrations can 
result inprecipitation, which can damage HPLC equipment. 
• The mobile phase should have a pH 2.5 and Ph 7.0 to maximize the lifetime of the 
column. 
• Reduce cost and toxicity of the mobile phase by using methanol instead of 
acetonitrile when possible minimizes the absorbance of buffer. 
• Use volatile mobile phase when possible, to facilitate collection of products and 
LC-MS analysis. Volatile mobile phases includes ammonium, acetate, ammonium 
phosphate, formic acid, and trifluoroacetic acid. Some caution is needed as these 
buffers absorb below 220nm. 
 Mobile phase used for HPLC are typically mixtures of organic solvents and 
water or aqueous Buffers. Physical properties of some HPLC solvents were 
summarized in table:3  
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Table: 3. Physical properties of common HPLC solvents 
Solvent MW BP 
RI 
(25OC) 
UV 
λ Cut-
off(nm) 
Density 
g/ml(25Oc) 
Viscosity 
CP(25OC) 
Dielectic 
constant 
Acetonitrile 41.0 82 1.342 190 0.787 0.358 38.8 
Dioxane 88.1 101 1.420 215 1.034 1.26 2.21 
Ethanol 46.1 78 1.359 205 0.789 1.19 24.5 
Ethyl 
Acetate 
88.1 77 1.372 256 0.901 0.450 6.02 
Methanol 32.0 65 1.326 205 0.792 0.584 32.7 
CH2CI2 84.9 40 1.424 233 1.326 0.44 8.93 
Isopropanol 60.1 82 1.375 205 0.785 2.39 19.9 
N-propanol 60.1 97 1.383 205 0.804 2.20 20.3 
THF 72.1 66 1.404 210 0.889 0.51 7.58 
a  :The wavelength at which the absorbance of 1cm is 1.0 
 
II. SOLVENT  DEGASSING  SYSTEM 
 The constituents of the mobile phase should be degassed and filtered before 
use. Several methods are employed to remove the dissolved gases in the mobile 
phase. They include heating and stirring, vacuum degassing with an aspirator, 
filtration through 0.45µfilters, vacuum degassing with an air-soluble membrane, 
helium purging ultra signification or purging or combination of these methods. HPLC 
systems are also provided an online degassing system, which continuously removes 
the dissolved gases from the mobile phase. 
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III. PUMP: 
High pressure pumps are needed to force solvents through packed stationary 
phase beds. Smaller bed particles requires higher pressures. There are many 
advantages to using smaller particles, but they may not be essential for all separations. 
The degree of flow of control also varies with pump expense. More expensive 
pumps include such state of the art technology as electronic feedback and 
multithreaded configurations. It is desirable to have an integrated degassing system, 
either helium purging, or membrane filtering. 
IV.  INJECTOR: 
Sample introduction can be accomplished in various ways. The simplest 
method. Is touse an injection value in more sophisticated LC systems, automatic 
sampling devices are incorporated where the sample is introduced with the help of 
auto samplers and microprocessors in liquid chromatography, liquid samples may be 
injected directly and solid samples need only be dissolved in an appropriate solvent. 
Sample introduction techniques can be used with a syringe an injection valve. 
V.  COLUMN: 
The heart of the system in the column. Many different reverse phase columns 
will provide excellent specificity for any particular separation. It is therefore best to 
routinely attempt separations with a standard C8 or C18 column and determine if it 
provides good separations. Reverse phase columns differ by the carbon chain length, 
degree of end capping and percent carbon loading. Diol, cyano and amino groups can 
also be used for reverse phase chromatography. Typical HPLC columns are 5,10,15, 
and 25cm in length and are filled with small diameter (3,5 or 10µm) particles. The 
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internal diameter of the columns is usually 4.6mm; this is considered the best 
compromise for sample capacity, mobile phase consumption, speed and resolution. 
However, if pure substances are to be collected (preparative scale),then larger 
diameter columns may be needed. 
VI.  DETECTOR: 
The detection of UV light absorbance offers both convenience and sensitivity 
for molecules. when a chromophore is present, the wavelength of detection for a drug 
should be based on its UV spectrum in the mobile phase and not in pure solvents. The 
most selective wavelength for detecting a drug is frequently the longest wavelength 
maximum to avoid interference from solvents, Buffers and Excipient. Other method 
of detection can be useful are required in some instances. 
1. Solute specific detectors (UV-Vis, Fluorescence, Electrochemical, Infra-red, 
Radio activity) 
2. Bulk property detectors (Refractive index, Viscometer, conductivity) 
3. Desolvation detector (Flame ionization etc) 
4. LC-MS detectors 
5. Reaction detectors 
VII. DATA SYSTEM: 
Since the detector signal is electronic, using modern data collection techniques 
can aid the signal analysis. In addition, some systems can store data in a form for 
highly sophisticated computer analysis at a later time. The main goal in using 
electronic data systems is to increase analysis accuracy and precision, while reducing 
operator attention. 
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PERFORMANCE CALCULATIONS: 
Calculating the following values (which can be included in a custom report)  
used to access overall system performance. 
           1. Relative retention 
           2.  Theoretical plates 
           3. Capacity factor 
           4. Resolution 
           5. Peak asymmetry 
           6. Plates per meter 
             The following information furnishes the parameters used to calculate these 
system performance values for the separation of two chromatographic components. 
(Note: where the terms w and t both appear in the same equation they must be 
expressed the same units) 
System suitability parameters: 
              The theory of chromatography has been used as the basis for system-
suitability tests, which are set of quantitative criteria that test the suitability of the 
chromatographic system to identify and quantify drug related samples by HPLC at 
any step of the pharmaceutical analysis. 
1. Relative retention: The time elapsed between the injection of the sample 
components in to the column and their detection is known as the retention time (Rt). 
α =(t2-ta) / (t1-ta) 
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Where, 
α =Relative retention 
t1= Retention time of the peak measured from point of injection. 
t2 = Retention time of the second measured from point of injection. 
ta = Retention time of an inert peak not retained by the column, measured from point of 
injection. 
2. Theoretical plates: 
n =16 (t R / w) 2 
Where, 
n =Theoretical plates 
tR = Retention time of the component 
W = width of the base of the component peak using tangent method. 
3. Capacity factor: The capacity factor describes the thermodynamic basis of the 
separation and its definition is the ratio of the amounts of the solute at the 
stationary and mobile phases within the analyte band inside the chromatographic 
column. 
K1 = (t2/t a)-1 
Where, 
K1 = Capacity factor 
ta = Retention time of an inert peak not retained by the column, measured from point of 
injection. 
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4. Resolution: the gap between two peaks 
R =2 (t2- t1) / (w2-w1) 
Where, 
R =Resolution between a peak of interest (peak 2) and the peak preceding it (peak 1) 
W2 = Width of the base of component peak 2 
W1 = Width of the base of component peak  
5. Peak asymmetry 
T =W0.05/ 2f 
Where, 
T = Peak asymmetry, or tailing factor. 
W0.05 = Distance from the leading edge to the tailing edge of the peak,measured at a 
point 5 % of the peak height from the baseline. 
f= Distance from the peak maximum to the leading edge of the peak. 
6. PLATE PER METER: 
N =n/L 
Where, 
N = plates per meter. 
L = column length in meters. 
Advantages:  
• HPLC separations can be accomplished in a minutes, in some cases even in 
seconds. 
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• High resolution of complex sample mixture into individual components. 
• Rapid growth of HPLC is also because of its ability to analyse substances that are 
unsuitable for Gas Liquid chromatographic (GLC) analysis due to non-volatility 
orthermal-instability. 
• Quantitative analysis are easily and accurately performed and errors of less than 1 
% are common to most HPLC methods. 
• Depending on sample type and detector used, it is frequently possible to measure 
10-9 g or 1 ng of sample. With special detectors, analysis down to 10-12 pg has 
been reported. 
• As HPLC is versatile, it can be applied to wide variety of samples like organic, 
inorganic, high molecular weight liquids, solids, ionic-nonionic compounds. 
Disadvantages: 
• HPLC instrumentation is expensive and represents a major investment for many 
laboratories. 
• HPLC cannot handle gas samples. 
• HPLC is poor identifier. It provides superior resolution but it does not provide the   
information that identifies each peak. 
• Only one sample can be analysed at a time. 
Finally, at present there is no universal and sensitive detector. 
4.  ANALYTICAL METHOD DEVELOPMENT 
Methods are developed for new products when no official methods are 
available. Alternate methods for existing (non-pharmacopoeial) products are 
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developed to reduce the cost and time for better precision and ruggedness. Trail runs 
are conducted, method is optimized and validated.  
When alternate method proposed is intended to replace the existing procedure, 
comparative laboratory data includes merits /demerits should be made available. 
The important factors, which to be taken into account to obtain reliable 
quantitative analysis , are 
     1. Careful sample and sample preparation 
     2. Appropriate choice of the column 
     3. Selection flow rate 
     4. Selection of detector wavelength 
     5. Selection of column temperature 
Documentation starts at the very beginning of the development process. A 
system for full documentation of development studies must be established. Analyte 
standard characterization. 
a) All known information about the analyte and its structure is collected i.e., 
physical and chemical properties. 
b) The literature for all type of information related to the analyte is surveyed. 
c) Using the information in the literatures and prints, methodology is adapted. The 
methods are modified where ever necessary. 
d) The required instrumentation is setup. Installation, operational and performance  
qualification of instrumentation using laboratory SOP,s are verified9. 
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HPLC method development is based on few basic steps which include: 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
                          
                                                             
 
 
Figure 2. Steps in HPLC method development 
Method goals: 
Analytical method goals are often defined as method acceptance criteria for 
peak resolution, precision, specificity, sensitivity. For instance, pharmaceutical 
methods for potency assays of an API typically require the following: 
• Minimal sample work-up (extra and inject if possible 
• Robust method that doesn’t require extensive execution. 
• Low cost per analysis. 
  
Information on sample, define separation Goals 
Need special HPLC procedure, sample   pre-treatment, etc? 
 
Choose detector and detector setting 
Choose LC method; preliminary run, estimate best 
Optimize separation conditions 
Check for problems or requirement for special procedures 
Recover purified material 
Quantitative calibration 
Qualitative method 
Validate method for release to 
routine laboratory 
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Table 4: separation goals in HPLC method development 
Goals Comment 
Resolution Precise and rugged quantitative analysis requires that Rs be 
greater than 1.5. 
%RSD Precision of retention time and peak area, ‹1-2%RSD. 
Range Linearity in the range of 50-150% of the lab label claim. 
Analysis time 5-30min ( 60min for complex samples) 
Separation time ‹5-10min is desirable for routine procedures. 
Quantification ≤2%(%RSD) for assays, ≤5% for less demanding analyses, 
≤15% for trace analyses. 
pressure ‹150 bar is desirable, ‹200bar is usually essential(new column 
assumed) 
Peak height Narrow peaks are desirable for large signal/ noise ratios 
 
Sample analyte information: 
The information is useful for the selection of appropriate sample preparation 
procedures as well as the initial detection and chromatographic modes. If data not 
available (e.g., PKa solubility), separate studies should be initiated as soon as 
possible. The sample related information is summarized in Table 4. 
Table 5: sample and analyte information 
Sample/analyte Information 
Sample Number of components concentration range of analytes 
Analyte (s) Chemical structure, molecular weight and functional groups 
PKa, Solubility, Chrpmophores, wavelength (max), Chiral 
centers, isomers 
Spectral data (MS,NMR, IR, and UV) 
Stability and toxicity 
Others Purity of reference standard materials 
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1. Careful sampling and sample preparation: 
Before beginning method development, it is need review what is known about 
the sample in to define the goals of separation. The sample related information that is 
important to summarized in table. The chemical composition of the sample can be 
provide valuable clues for the best choice of initial conditions for an HPLC 
separation. 
 Number of compounds present 
 Molecular weight of compounds  
 PKa values of compounds 
 UV spectra of compounds 
 Concentration range of compounds in samples of interest 
 Sample solubility 
2. Separation goals 
The goals of HPLC separation need to be specified clearly, which include 
• The use of HPLC to isolate purified sample components for spectral identification 
Or quantitative analysis 
• It may necessary to separate all degradants or impurities from a product for reliable 
content assay or not 
• In quantitative analysis, the required levels of accuracy and precision should be 
known 
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• Whether a single HPLC procedure is sufficient for raw materials or one or more 
different  procedures are desired for formulations    
• When the number of samples for analysis at one time is greater than 10, a run time 
of less than 20 minutes often will be important. Knowledge on the desired HPLC 
equipment. 
• HPLC equipment, HPLC experience and academic training do to operators have 
Sample preparation: samples come in various forms 
o Solutions ready for injection 
o solutions that require dilution, buffering, addition of an internal                                         
standard or other volumetric manipulation 
o solids must be dissolved or extracted 
o Samples that require pretreatment to remove interference and / or to protect the 
column or equipment from damage 
3. Appropriate choice of the column: 
The selection of the column in HPLC is somewhat similar to the selection of 
column in G.C, in the sense that, in the adsorption and partition modes, the separation 
mechanism is based on inductive forces, dipole-dipole interaction and hydrogen bond 
information. 
Column plays the important role in achieving the chromatographic separation. 
The following parameters should be considered while selecting a column  
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i. Length and diameter of the column 
ii. Packing material 
iii. Size and shape of the particles 
iv. Pore size, surface area and end capping 
v. Percentage of carbon loading columns with silica as a packing material used 
widely in normal phase chromatography, where the eluent  (mobile phase) is 
non-polar consisting of various organic solvents and the stationary phase is 
polar. The silanol groups on the surface of the silica give it a polar character. 
In reverse phase chromatography a wide variety of columns is available 
covering a wide range of polarity by cross linking the silanol groups with alkyl chains 
like C6, C8, C18 and Nitrile groups (-CN), phenyl groups (-C6H6) and amino groups (-
NH2) 
ORDER OF THE SILICA BASED COLUMNS 
                                I------Non polar------Moderately polar------Polar------I 
                                C18<C8<C6‹ Phenyl ‹ Amino ‹ Cyano ‹ Silica 
4. Selection of flow rate. 
Flow rate is selected based on the follows 
• Retention time 
• Column composition 
• Separation impurities 
• Peak symmetry 
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Preferably flow rate shall not be more than 2.5 mL/Min. a flow rate that gives 
least retention times, good peak symmetries, least back pressure and better separatiotn 
of impurities from API peak shell be selected. 
5. Selection of detector wavelength: 
Selection of detector wavelength is a critical step in finalization of the 
analytical method. To determine the exact wavelength standard API is injected into 
chromatographic system with photo Diode array detector and the wavelength, which 
gives higher response for the Compound. 
6. Selection of column temperature: 
Ambient temperature is always preferred as a column temperature. However if 
the peak Symmetry could not be achieved then the column temperature can be varied 
between 300To
 800 c. if a column temperature above 800c is found necessary, packing 
material which can Withstand to that temperature shall be chosen. The increase in 
column temperature generally will result in reduction in peak asymmetry and peak 
retentions. 
5. ANALYTICAL METHOD VALIDATION: 
Method validation can be defined as (ICH) “Establishing documented 
evidence, which Provides a high degree of assurance that a specific activity will 
consistently produce a desired result or product meeting is predetermined 
specifications and quality characteristics”. 
Method validation study include system suitability, linearity, precision, 
accuracy, specificity,  ruggedness, robustness, limit of detection, limit of 
quantification and stability of samples, reagents, instruments13. 
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VALIDATION DEFINITION: 
FDA defines validation as “Establishing documented evidence, which 
Provides a high degree of degree of assurance that a specific process will consistently 
produce a product of predetermined specifications and quality attributes. 
OBJECTIVE OF METHOD VALIDATION: 
The objective of validation is to form a basis for written procedure for 
production and control, which are designed to assure that the drug products have the 
identity, quality, and purity. 
TYPES OF ANALYTICAL PROCEDURES: 
i. Identification tests 
ii. Quantitative tests for impurities content 
iii. Limit test for control of impurities 
iv. Quantitative tests of the active moiety in samples of drug substances or drug 
product or             
v. Other selected components(s) in the drug product. 
vi. Dissolution testing for drug products 
vii. Particle size determination for drug substances. 
6. VALIDATION PARAMETERS (ICH). 
Typical validation study include system suitability 
I. Accuracy 
II. Precision 
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III. Specificity 
IV. Linearity 
V. Detection limit 
VI. Quantification limit 
VII. Range 
VIII. Robustnes 
1. System suitability 
Prior to the analysis of samples of each day, the operator that the HPLC system 
and proceduce are capable of providing data of acceptable quality. This is 
accomplished with system suitability experiments, which can be defined as tests to 
ensure that the method can generate results of acceptable accuracy and precision. The 
requirements for system suitability are usually developed after method development 
and validation has been completed. 
Table : 6. System suitability parameters and Recommendation 
Parameter Recommendation 
Capacity factor 
 
 
The peak should be well-resolved  from 
Other peaks and the void volume, 
Generally K› 2.0 
Repeatability RSD ≤1% N ≥ 5 is desirable 
Relative retention Not essential as long as the resolution is Stated 
Resolution 
 
 
 
RS of › 2 between the peak interest and   
The closes to eluting potential  
Interferent (impurity, excipient, degradation product, internal 
standard,  etc,) 
Tailing factor T of ≤ 2 
Theoretical plates N› 2000 
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Non-Interference of placebo: 
The portion of specificity evaluation applies to the finished drug product only. 
Excipients present in the formulation should be evaluated and must not interfere with 
the detection of the analyte. 
2. Linearity 
The linearity of a method is a measure of how well a calibration plot of 
response vs. concentration approximates a straight line. Linearity can be assessed by 
performing Single measurement at several analyte concentrations. The data is then 
processed using a linear least- squares regression. The resulting plot slope, intercept 
and correlation coefficient Provide the desired information on linearity. 
3. Precision 
Precision can be defined as “The degree of agreement among individual test 
results when The procedure is applied repeatedly to multiple samplings of a 
homogenous sample”. A More comprehensive definition proposed by the 
international conference on Harmonization (ICH) divides precision into three types. 
1. Repeatability 
2. Intermediate precision and 
3. Reproducibility 
Repeatability: is the precision of a method under the same operating 
conditions over a short  period of time. 
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Intermediate precision: is the agreement of complete measurements 
(including standards) when the same method is applied many times within the same 
laboratory. 
Reproducibility: examine the precision between laboratories and is often 
determined in collaborative studies or method transfer experiments. 
4. Accuracy: 
The accuracy of a measurement is defined as the closeness of the measured 
value to the true value. In a method with high accuracy, a sample (whose “true value” 
is known) is analyzed and the measured value is identical to the true value. Typically, 
accuracy, is represented and determined by recovery studies. There are three ways to 
determine accuracy: 
1. Comparison to a reference standard 
2. Recovery of the analyte spiked into black matrix or 
3. Standard addition of the analyte. 
It should be clear how the individual or total impurities are to be determined. 
e.g., weight/ weight or area percent in all cases with respect to the major analyte. 
5. Specificity/ selectivity 
The terms specificity are often used interchangeably. According to ICH, the 
term specific generally refers to a method that produces a response for a single analyte 
only while the term selective refers to a method which provides responses for a 
number of chemical entities that may or may not be distinguished from each other. If 
the response is distinguished from all other responses, the method said to be selected. 
Since there are very few methods that respond to only one analyte, the term selectivity 
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is more appropriate. The analyte should have no interference from other extraneous 
components and be well resolved from them. A representative chromatogram or 
profile should be generated and submitted to show that the extraneous peak either by 
addition of known compounds or samples from stress testing are baseline resolved 
from the parent analyte. 
6. Ruggedness: 
The  ruggedness of an analytical method is the degree of reproducibility of test 
results Obtained by the analysis of the same samples under a variety of normal test 
conditions Such as different laboratories, different analysts, using operational and 
environmental Conditions that may differ but are still within the specified parameters 
of the assay. The Testing of the ruggedness is normally suggested when the method is 
to be used in more than One laboratory. Ruggedness normally expressed as the lack of 
the influence on the test results of operational and environmental variables of the 
analytical method. 
For the determination or ruggedness, the degree of reproducibility of test result 
is determined as a function of the assay variable. This reproducibility may be 
compared to the precision of the assay under normal conditions to obtain a measure of 
the ruggedness of the analytical method. 
7. Robustness: 
The concept of robustness of an analytical procedure has been defined by the 
ICH as “a Measure of its capacity to remain unaffected by small, but deliberate 
variations in methodParameters”. A good practice is to vary important parameters in 
the method systematically and measure their effect on separation. The variable 
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method parameters in HPLC technique May involves flow rate, column temperature, 
sample temperature, pH and mobile phase composition. 
8. Stability: 
 To generate reproducible and reliable results, the samples, standards, and 
Reagents used for the HPLC method must be stable for a reasonable time (e.g., one 
day, One week, one month, depending on need). Therefore, a few hours of standard 
and Sample solution suitability can required even for short (10 min) separation. When 
more than one sample is analyzed (multiple lots of one sample or samples from 
different Storage conditions from a single lot), automated, overnight runs often are 
performed for Better lab efficiency such practices add requirements for greater 
solution stability. 
9. Limit of Detection: 
 Limit of detection (LOD) is the lowest concentration of analyte in a sample 
that can be Detected, but the necessarily quantitated, under the stated experimental 
conditions.  
• Based on visual Evaluation 
• Based on the standard Deviation of the Blank 
• Based on the calibration curve 
• Based on signal-to-noise: A signal-to-noise ratio of 3 or 2:1 is acceptable 
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LOD may be expressed as 
LOD =3.3σ/s 
Where,           σ = the standard deviation of the response 
                       S= the slope of the calibration curve 
The slope S  may be estimated from the calibration of the analyte. 
10. Limit of quantification:  
Limit of quantification is the lowest concentration of analyte in a sample that 
can be Determined with acceptable precision and accuracy under the stated 
experimental conditions. Several approaches for determining the quantification limit 
are possible. 
• Based  on visual Evaluation 
• Based on standard Deviation of the blink 
• Based on the calibration curve 
• Based on the signal-to-Noise Approach: A typical signal-to-Noise is 10:1 
LOQ  may be expressed as   
LOQ  = 10σ /s 
Where, σ = standard deviation of the response 
S= the slope of the calibration curve12 
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PARACETMOL19: 
Structure: 
Chemical name: 
IUPAC Name 
Molecular formula   
Molecular Weight     
Solubility                  
CAS number            
Biological half life 
Description: 
Acetaminophen, also known as paracetamol, is commonly used for its 
analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it 
lacks anti-inflammatory, antiplatelet, and gastric ulcerative 
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2. DRUG PROFILE 
 
Fig No : 3 Structure of Paracetmol 
: N-(4-hydroxyphenyl)acetamide 
 : C8H9NO2 
: 151.1626gm/mol 
: Soluble in water, methanol 
: 103-90-2 
: 1 to 4 hours 
effects. 
 
Drug Profile 
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Mechanism of action: 
Acetaminophen is thought to act primarily in the CNS, increasing the pain 
threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-
3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen 
does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-
inflammatory affects. While aspirin acts as an irreversible inhibitor of COX and 
directly blocks the enzyme's active site, studies have found that acetaminophen 
indirectly blocks COX, and that this blockade is ineffective in the presence of 
peroxides. This might explain why acetaminophen is effective in the central nervous 
system and in endothelial cells but not in platelets and immune cells which have high 
levels of peroxides. Studies also report data suggesting that acetaminophen selectively 
blocks a variant of the COX enzyme that is different from the known variants COX-1 
and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action 
is still poorly understood, but future research may provide further insight into how it 
works. The antipyretic properties of acetaminophen are likely due to direct effects on 
the heat-regulating centres of the hypothalamus resulting in peripheral vasodilation, 
sweating and hence heat dissipation. 
Indications : For temporary relief of fever, minor aches, and pains. 
Absorption : Rapid and almost complete 
Protein binding : 25% 
Metabolism : Acetaminophen primarily undergoes glucuronidation (45-55% 
of the dose) in which this process is facilitated by UGT1A1, UGT1A6, UGT1A9, 
UGT2B15 in the liver or UGT1A10 in the gut. 30-35% of the dose undergoes 
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sulfation. This biotransformation is facilitated by SULT1A1, SULT1A3, SULT1A4, 
SULT1E1 and SULT2A1. A small percentage of acetaminophen is oxidized by 
CYP2E1 to form N-acetyl-p-benzo-quinone imine (NAPQI), a toxic metabolite which 
is then conjugated to glutathione and excreted renally. Studies suggest that CYP3A4 
and CYP2E1 are the primary cytochrome P450 isozymes responsible for the 
generation of toxic metabolites. Accumulation of NAPQI may occur if primary 
metabolic pathways are saturate. 
Pharmacodynamics: Acetaminophen (USAN) or Paracetamol (INN) is a 
widely used analgesic and antipyretic drug that is used for the relief of fever, 
headaches, and other minor aches and pains. It is a major ingredient in numerous cold 
and flu medications and many prescription analgesics. It is extremely safe in standard 
doses, but because of its wide availability, deliberate or accidental overdoses are not 
uncommon. Acetaminophen, unlike other common analgesics such as aspirin and 
ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is 
not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or 
NSAIDs. At therapeutic doses acetaminophen does not irritate the lining of the 
stomach nor affect blood coagulation, kidney function, or the fetal ductusarteriosus 
(as NSAIDs can). Like NSAIDs and unlike opioid analgesics, acetaminophen does 
not cause euphoria or alter mood in any way. Acetaminophen and NSAIDs have the 
benefit of being completely free of problems with addiction, dependence, tolerance 
and withdrawal. Acetaminophen is used on its own or in combination with 
pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, 
doxylamine, codeine, hydrocodone, or oxycodone. 
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FLUPIRTINE MALEATE
Structure: 
Fig 
Chemical name: 
IUPAC Name : 
  
Molecular formula : 
Molecular Weight : 
CAS number : 
Biological hal life : 
Solubility : 
  
Description : 
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid
analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not 
approved for use in the U.S. or Canada, but is currently in phase II trials for the 
treatment of fibromyalgia.
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20: 
No : 4 Stuctue of Flupirtine maleate 
Ethyl N-(2-amino-6-{[(4-fluorophenyl)methyl]amino}pyridin
3-yl) carbamate 
C15H17FN4O2 
304.3195 gm/mol 
56995-20-1 
6.5 hrs (average), 11.2-16.8 hrs (average 14 hrs) (elderly)
Water soluble, organic solvents like ethanol.
Dimethylfomamide 
 
Drug Profile 
 
 
- 
 
 DMSO,  
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Mechanism of action: 
Flupirtineupregulates Bcl-2, increases glutathione levels, activates an inwardly 
rectifying potassium channel, and delays loss of intermitochondrial membrane 
calcium retention capacity. Flupirtine acts like a NMDA receptor antagonists, but 
does not bind to the receptor. One study concluded that the discriminative effects of 
flupirtine are neither of opioid nor of alpha-1 adrenergic type, but are primarily 
mediated through alpha-2 adrenergic mechanisms [PMID: 2901483]. 
Indications : Investigated for use/treatment in fibromyalgia. 
Absorption : Bioavailability: 90% (oral), 70% (rectal) 
Metabolism: Hepatic to 2-amino-3-acetylamino-6-(para-fluorobenzylamino) pyridine 
(which has 20-30% the analgesic potential of its parent compound) and Para-
fluorohippuric acid. 
Route of elimination: 72% of flupirtine and its metabolites appear in urine and 18% 
appear in faeces. 
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3. LITERATURE REVIEW 
1. K. V. Lalitha et al,21 A simple, selective, rapid, precise and economical 
reverse phase high performance liquid chromatographic (RP-HPLC) method has been 
developed for the simultaneous estimation of Paracetamol (PARA) and Flupiritine 
Maleate (FLU) from pharmaceutical formulation. The method is carried out on 
Agilent C18 (25 cm x 4.6 mm i.d., 5 µ) column with a mobile phase consisting of 
Methanol : Water (0.2% TEA, adjusted to pH 3.0 using orthophosphoric acid) in the 
ratio of 90:10 v/v. The retention time of Paracetamol and Flupiritine Maleate is 3.2 
min and 5.1 min respectively with the flow rate of 1mL/ min with VWD detection at 
239 nm. The linear regression analysis data for the linearity plot showed good linear 
relationship with correlation coefficient value for Paracetamol and Flupiritine Maleate 
were R2=0.9995 and R2=0.9996 in the concentration range of 9-63 µg. mL-1 , 3-21 
µg. mL-1 respectively. The relative standard deviation for intra-day precision has 
been found to be lower than 2.0 %. The method is validated according to the ICH 
guidelines. The developed method is validated in terms of specificity, selectivity, 
accuracy, precision, linearity, limit of detection, limit of quantitation and solution 
stability. The proposed method can be used for simultaneous estimation of these drugs 
in marketed dosage forms. 
2. Umang Shah et al,22 Two methods for simultaneous estimation of 
Paracetamol and Flupirtine maleate in combineddosage form have been developed. 
The first method is the aplication of Q-analysis method (absorbance ratio),which 
involves the formation of Q-absorbance equation at 302 nm (isobestic point) and at 
248 nm, themaximum absorbance of Paracetamol. The linearity ranges for PCM and 
FLU were 2-35 µg/ml and 0.5- 70µg/ml, respectively. The second method was based 
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on the use of first derivative spectroscopy, in whichderivative amplitudes were 
measured at selected wavelengths (234 nm ZCP of FLU for PCM and 34 nm ZCPof 
PCM for FLU), without mutual interference. The linearity ranges for PCM and FLU 
were 2-34 µg/ml and 2- 65 µg/ml, respectively. The acuracy of the methods were 
asesed by recovery studies and was found to be9.93% ±0.549 and 10.05% ±0.65 for Q 
absorbance ratio method and 9.54% ±0.591 and 9.41% ±0.792 forfirst derivative 
method, for PCM and FLU, respectively. These methods are simple, acurate and 
rapid; thoserequire no preliminary separation and thereforecan be used for routine 
analysis of both drugs in quality controllaboratories. 
3. Haritha et al,23The present study describes a simple, accurate and precise 
RP-HPLC Technique for the simultaneous determination of Flupirtine maleate and 
Paracetamol in pharmaceutical dosage form. The method involves an isocratic elution 
of drug in a stationary phase of Phenomenex, C18 (150mm × 4.6mm, 5µm) column 
using a mobile phase composition of methanol and 0.1% (v/v) orthophosphoric acid 
in the composition ratio of 60:40 v/v with a flow rate of 0.8 mL/min at 270 nm of 
detection. The injection volume is 20 µL. the method has been validated for 
specificity, linearity, range, precision, accuracy, limit of detection, limit of 
quantification, ruggedness and robustness.The retention times for Flupirtine maleate 
and Paracetmol are about 3.07 and 4.63 minutes respectively. Quantitative linearity 
was observed over the concentration range of 10.08 to 302.51 µg/mL for Flupirtine 
maleate and 4.99 to 99.80 for Paracetamol respectively. The regression equations of 
concentration of Flupirtine maleate and Paracetamol are found to be y = 1774x+4755, 
y = 39182x + 64154 respectively where y is the peak area and x is the concentration 
of drug (µg/mL). The % recovery of Flupirtine maleate and Paracetamol are found to 
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be in the range of 97% to103 %. All the validation parameters are within the 
acceptance range 
4. GayatriGullipalli et al,24 A simple, specific, accurate, precise and 
economical reverse phase high performance liquid chromatographic (RP-HPLC) 
method has been developed for the simultaneous estimation of flupiritine maleate 
(FLU) and paracetamol (PARA) in bulk and pharmaceutical dosage form. The two 
components were separated using Inertsil ODS, C18 (250 mm × 4.6 mm id, 5 µm 
particle size) column by isocratic elution using mobile phase composition of 
potassium dihydrogen phosphate: methanol (70: 30) and pH 3.0 was adjusted with 
orthophosphoric acid. Flow rate used was 1ml/min and detection was carried out at 
217nm. Injection volume is 5 µl. The retention time of flupiritine maleate and 
paracetamol is 2.553 min and 3.620 min respectively. As per ICH guidelines the 
method has been validated in terms of specificity, linearity, range, accuracy, 
precision, limit of detection, limit of quantitation, robustness. The method was found 
to be linear in the range of 50-150µg/ml(R2=0.999) for flupiritine maleate and 10-30 
µg/ml (R2=0.999) for paracetamol. The limit of detection and limit of quantitation 
were found to be 2.14 and 7.13 for flupiritine maleate and 2.52 and 8.41 for 
paracetamol. Flupiritine maleate and paracetamol has the recoveries of 100.2% and 
100.8% respectively and their relative standard deviations were less than 2%. All the 
validation parameters met the acceptance criteria. The proposed method can also be 
used for simultaneous estimation of these drugs in marketed dosage form. 
5. P. Giriraj et al,25A new, simple, precise, accurate, reproducible, and efficient 
Vierordt’s method or simultaneous equation method was developed and validated for 
simultaneous estimation of paracetamol and flupirtine maleate in pure and 
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pharmaceutical dosage form. The method was based on the measurement of absorbance 
at two wavelengths 245nm and 344.5nm,  ofparacetamol and flupiritine maleate in 
0.1N HCl correspondingly. Calibration curves of paracetamol and flupiritine maleate 
were found to be linear in the concentration ranges of 5–15µg/mL and 1.53–
4.61µg/mL, respectively, with their correlation coefficient values (R2) 0.999. LOD 
and LOQ were 185.90ng/mL and 563.38ng/mL for paracetamol and 78.89ng/mL 
and 239.06ng/mL for flupiritine maleate. In the precision study, the % RSD value was 
found within limits (%). The percentage recovery at various concentration levels varied 
from 99.18 to 100.02% for paracetamol and 98.47 to 100.09% for flupiritine maleate 
confirming that the projected method is accurate. It could be concluded from the results 
obtained in the present investigation that this method for simultaneous estimation of 
paracetamol and flupirtine maleate in pure and tablet dosage form is simple, accurate, 
precise, and economical. The proposed method can be applied successfully for the 
simultaneous estimation of paracetamol and flupiritine maleate in pure and 
pharmaceutical dosage form. 
6. A.ALIEKYA et al26, This communication describe simple, sensitive, rapid, 
accurate, precise and cost effective First derivative spectrophotometric zero crossing 
method for the simultaneous determination of Paracetamol and Flupiritine Maleate in 
combined dosage form. The utility of first derivative data processing program is its 
ability to calculate unknown concentration of components of interest in a mixture 
containing an interfering component. The first order derivative absorption at 248 nm 
(zero cross point for Paracetamol) was used for estimation of Flupiritine Maleate and 
254 nm (zero cross point for Flupiritine Maleate) was used for estimation of 
Paracetamol. Linear correlation was obtained between absorbance and concentrations 
of PARA and FLU in the concentration ranges of 2-14 µg/ml and 6.5-45.5 µg/ml, with 
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R2value 0.999 at both the wavelength respectively. The linearity of the 
calibrationcurve was validated by the high values of correlation coefficient of 
regression. The RSD values of PARA and FLU were found to be less than 2%. LOD 
and LOQ values for PARA were found to be 0.122 and 0.402µg/ml at 254 nm 
respectively. LOD and LOQ values for FLU were found to be 0.908 and 3.253 µg/ml 
at 248 nm, respectively. 
7. GollaMurali Mohan J et al,27A simple, selective, rapid, precise and 
economical reverse phase high performance liquid chromatographic (RP-HPLC) 
method has been developed for the simultaneous estimation of Paracetamol (PARA) 
and Flupiritine Maleate (FLU) from pharmaceutical formulation. The method is 
carried out on Agilent C18 (25 cm x 4.6 mm i.d., 5 µ) column with a mobile phase 
consisting of Methanol : Water (0.2% TEA, adjusted to pH 3.0 using orthophosphoric 
acid) in the ratio of 90:10 v/v. The retention time of Paracetamol and Flupiritine 
Maleate is 3.2 min and 5.1 min respectively with the flow rate of 1mL/ min with 
VWD detection at 239 nm. The linear regression analysis data for the linearity plot 
showed good linear relationship with correlation coefficient value for Paracetamol 
and Flupiritine Maleate were R2=0.9995 and R2=0.9996 in the concentration range of 
9-63 µg. mL-1 , 3-21 µg. mL-1 respectively. The relative standard deviation for intra-
day precision has been found to be lower than 2.0 %. The method is validated 
according to the ICH guidelines. The developed method is validated in terms of 
specificity, selectivity, accuracy, precision, linearity, limit of detection, limit of 
quantitation and solution stability. The proposed method can be used for simultaneous 
estimation of these drugs in marketed dosage forms. 
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4. AIM & OBJECTIVE 
Existing literature reveals that Paracetmol and Flupirtine maleate can be 
analyzed by HPLC using UV detection, TLC, HPTLC, HPLC in bulk material and 
pharmaceutical forms. 
A comprehensive, validated and simple analytical method development and 
validation of Paracetmol and Flupirtine maleate tablets is, therefore, crucial. HPLC 
With PDA detector is a good selection as PDA detector is available in most 
laboratories, Therefore, in proposed project a successful attempt has been made to 
develop, simple, Accurate, and economic methods for analysis of Paracetmol and 
Flupirtine maleate tablets validated. 
OBJECTIVE 
The objective of the present work is to development and validate a HPLC 
method with PDA detector for the development and validation Paracetmol and 
Flupirtine maleate of tablets. To be employed in routine and stability tests. In the 
method development of Paracetmol and Flupirtine maleate we have decided to carry 
out our project work by incorporating the Reverse phase High performance Liquid 
chromatography (HPLC). Then the developed method will be validated according to 
ICH guidelines for its various Parameters. 
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5. PLAN OF WORK 
In order to develop a simple, reliable and an accurate method development and 
validation of Paracetmol and Flupirtine maleatein pharmaceutical dosage form by 
Reverse phase HPLC and validate the method for its repeatability and reproducibility.  
Plan of the proposed work includes the following steps: 
• Selection of drug and literature survey. 
• Solubility studies and optimization of conditions. 
• Analytical method(s) development using HPLC etc., 
• Assay of the drugs(s) in marketed formulations using the proposed method(s). 
• Procurement of raw materials. 
• Establishment of system suitability parameters. 
• Trails for the method development of Paracetmol and Flupirtine maleate. 
• Setting of the optimized method. 
• Validation of the optimized method for Paracetmol and Flupirtine maleate. 
Validation parameters include: 
 System suitability 
 Specificity 
 Method precision 
 Linearity 
 Accuracy 
 Range 
 Robustness                      
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6. INSTRUMENTS/EQUIPMENT DETAILS 
Instruments: 
• WATERS HPLC, Model: Aliance 2695, Photo diode array detector (PDA), with 
anautomated sample injector. The output signal was monitored and integrated 
using Empower 2 software. AgelentC18 (4.6 x 250mm, 5 µm, Make: Waters) 
column was used for separations. 
Table No.: 7 List of Equipments 
S. No. Equipment’s Software Model Company 
     1 Electronic Balance NA ER200A ASCOSET 
     2 Ultra-Sonicator NA SE60US ENERTECH 
     3 Heating Mantle NA BTI BIO TECHNICS INDIA 
     4 Thermal oven NA --------- NARANG 
     5 pH Meter NA AD102U ADWA 
     6 Filter Paper 0.45 microns NA --------- MILLI PORE 
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MATERIALS: 
List of Chemicals and Reagents used 
Table No. : 8 List of chemicals and reagents 
S. No. Chemicals/standards and reagents Grade Make 
1 Ortho-Phosphoric Acid AR Finar 
2 Methanol HPLC Merck 
3 Water HPLC Loba Chemi 
4 Paracetmol NA Dr. Reddy’s 
5 Flupirtine maleate NA Dr. Reddy’s 
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7. METHOD DEVELOPMENT 
TRAIL 1: 
Mobile phase                     : Acetonitrile: methanol (50:50) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Hypersil (250*4.6mm, 5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 1ml/min 
 
 Name Retention 
Time 
Area USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
1  2.927 22524731  6.76 3585 
 
Figure No : 5 Typical chromatogram of trail 1 
Observation : Peaks were not eluted 
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TRAIL 2: 
Mobile phase :  Acetonitrile: methanol (70:40) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Hypersil (250*4.6mm, 5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 1ml/min 
 
 Name Retention 
Time 
Area Height USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
2  3.638 2276685 356851 3.28 1.92 7325 
1  2.974 9557650 1041912  1.69 2633 
 
Figure no : 6 Typical chromatogram of trail 2 
Observation: Peaks were not eluted 
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TRAIL 3: 
Mobile phase                   : Acetonitrile: methanol (60:40) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Agilent (250*4.6mm, 5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 1ml/min 
 
 Name Retention 
Time 
Area USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
1  3.000 20493838  1.33 5781 
 
Figure no: 7 Typical chromatogram of trail 3 
Observation: Second peak was not eluted 
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TARIL: 4 
Mobile phase                     : OPA buffer pH3.0: methanol (50:50) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Agilent (250*4.6mm, 5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 1ml/min 
 
 Name Retention Time Height 
USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
2  2.967 390401 4.03 1.23 5413 
1  2.251 187896  1.31 2091 
 
Figure no: 8 Typical chromatogram of trail 4 
Observation: Two Peaks were eluted, but plate count fails. 
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TRAIL: 5 
Mobile phase                     : OPA buffer pH3.0: methanol (80:20) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Agilent (250*4.6mm,5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 0.8ml/min 
 
 Name Retention 
Time 
Area USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
1  5.729 6539367  1.06 3723 
2  9.469 14430602 8.81 1.07 6820 
 
Figure No : 9 Typical chromatogram of trail 5 
Observation : RT was found to be more 
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TRAIL: 6 
Mobile phase                     : OPA buffer pH3.0: methanol (70:30) 
Auto sample temperature  : 25oc 
Injection volume               : 10µL 
Column                             : C18 Agilent (250*4.6mm,5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 0.8/min 
 
 Name Retention Time Area 
USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
2  5.729 900158 10.06 1.04 3836 
1  2.988 327285  1.28 5532 
 
Figure no: 10 Typical chromatogram of trail 6 
Observation: RT was found to be more 
 
 
2.
98
8
5.
72
9
AU
0.00
0.02
0.04
0.06
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00
Chapter 7 Methodology 
Dept. of Pharmaceutical Analysis  54 J.K.K. Nattraja College of Pharmacy 
TRAIL 7: 
Mobile phase                     : OPA buffer pH3.0: methanol (65:35) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18 Agilent (250*4.6mm,5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 0.8/min 
 
 Name Retention Time Area 
End 
Time 
USP 
Resolution 
USP 
Tailing 
USP Plate 
Count 
2  4.721 1078997 4.941 8.864 1.21 13930 
1  3.335 920750 3.503  1.25 8503 
 
Figure no: 11 Typical chromatogram of trail 7 
Observation: RT was found to be more 
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8. OPTIMIZED METHOD 
Chomatographic parameters: 
Mobile phase                    : OPA buffer pH3.0: methanol(65:35) 
Auto sample temperature : 25oc 
Injection volume               : 10µL 
Column                             : C18AgIlent(250*4.6mm,5µ) 
Detector wavelength         : 280nm 
Flow rate                           : 0.8ml/min 
Procedure: 
              Inject 10µL of standard, sample into chromatographic system and measure 
the areas for the Paracetmol and Flupirtine maleate peeks and calculate the % assay 
by using the formula 
 
Fig No:12 Chromatogram for optimized method 
Observation: Peeks are well separated all the parameters are within the limits. 
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PREPARATION OF MOBILE PHASE: 
Transfer 1000ml of HPLC water into 1000ml of beaker and adjust pH 3.0 with 
orthophosphoricacid(OPA). 
Transfer the above solution 650ml and 350ml of buffer and methanol is used 
as mobile phase. They are mixed and sonicated for 20min. 
PREPARATION OF THE PARACETMOL AND FLUPIRTINE 
MALEATESTANDARD AND SAMPLE SOLUTION: 
PREPARATION OF STANDARD SOLUTION: 
Accurately weigh and transfer 325mg of Paracetmol and 100mg of Flupirtine 
maleate into 100ml of volumetric flask and add 10ml of Methanol and sonicate 10min 
(or) shake 5min and make with water. Transfers the above solution into 5ml into 25ml 
volumetric flask dilute to volume with water. 
PREPARATION OF SAMPLE STOCK SOLUTION: 
Commercially available 20 tablets ware weighed and powdered the powdered 
equivalent to the 802.04mg of Paracetmol and Flupirtine maleate of active ingredients 
were transfer into a 100ml of volumetric flask and add 10ml of Methanol and sonicate 
20min (or) shake 10min and makeup with water.  
Transfers above solution 5ml into 25ml of the volumetric flask dilute the 
volume with Methanol. And the solution was filtered through 0.45µm filter before 
injecting into HPLC system. 
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9. METHOD VALIDATION 
1. SYSTEM SUITABILITY: 
 Tailing factor for the peaks due to Paracetmol and Flupirtine maleatein 
standard solution should not be more than 2.0.Theoretical plates for the Paracetmol 
and Flupirtine maleate peaks in standard solution should not be less than 2500. 
2. SPECIFICITY: 
 Solution of standard sample and placebo were prepared as per test procedure 
and injected into the HPLC system.  
Acceptance criteria: 
 Chromatogram of standard and sample should be identical with near Retention 
time. 
Blank interference: 
 A study to establish the interference of blank was conducted. Diluent was 
injected into HPLC system as per the test procedure. 
Acceptance criteria: 
 Chromatogram of blank should not show any peak at the retention time of 
analytepeak. There is no interference due to blank at the retention time of analyte. 
Hence the method is specific. 
3. LINEARITY 
 Prepare a series of standard solutions and inject into HPLC system. Plot the 
graph of standard versus the actual concentration in µg/ml and determine the 
coefficient of correlation and basis for 100% response. 
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Acceptance criteria: 
 Linearity regression coefficient of average peak area response of replicate 
injections plotted against respective concentration should not be less than 0.999. The 
% y-intercept as obtained from the linearity data (without extrapolation through origin 
0, 0) should be within ±2.0. 
Statistical Evaluation: 
 A graph between the concentration and the average area was plotted. Points 
for linearity were observed. Using the method of least squares, a line of best fit was 
taken and the correlation Coefficient, slope and, y-intercept were calculated.  
4. PRECISION: 
Preparation of sample: 
 Transfer the 802.04mg of sample into a 100ml of volume at flask and add 10ml of 
water and 10ml of Methanol andsonicate 20min and makeup with water. Transfer 
the above solution into 5ml into 25ml volume metric flask dilute to the volume 
with water. 
 The method precision parameters were evaluated from sample chromatograms 
obtained, by calculating the % RSD of peek areas from 6 replicate injection. 
Acceptance criteria: The injection reproducibility requirements are met if the %RSD 
for peak areas is not more than 2.0 and for retention times is not more than 2.0. 
5. RECOVERY/ACCURACY 
 Recovery study can be performed in the concentration range of 80%, 100% to 
120% of the target concentration of the test. Minimum 3 concentrations are 
recommended. 
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Acceptance criteria: 
      The average percentage recovery was between 97-103% and Relative 
standard deviation of these recovery concentrations was less than 2%. 
6. LIMIT OF DETECTION 
 The sensitivity of measurement of Paracetmol and Flupirtine maleateby use of 
proposed method was estimated in terms of the limit of detection (LOD). The LOD 
was calculated calculated by the use of signal to noise ratio. In order to estimate the 
LOD value, the blank sample was injected six times and peak area of this blank was 
calculated as noice level. The LOD was calculated as three times the noise level. 
                                                LOD= 3.3 σ / S 
Where, 
σ  = standard deviation of intercepts of calibration curves 
S = mean of slopes of the calibration curves 
The slope S may be estimated from the calibration curve of the analyte. 
7. LIMIT OF QUANTIFICATION: 
 The sensitivity of measurement of Paracetmol and Flupirtine maleateby the 
use of proposed method was estimated in terms of limit of quantification (LOQ). The 
LOQ was calculated by the use of signal to noise ratio. In order to estimate the LOQ 
value, the blank sample was injected six times and thepeak area of this blank was 
calculated at noise level. TheLOQ was calculated as ten times the noise value gave 
the LOQ. 
LOQ = 10 σ / S 
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Where, 
σ  = standard deviation of intercepts of calibration curves 
S = mean of slopes of the calibration curves 
The slope S may be estimated from the calibration curve of the analyte. 
8.ROBUSTNESS: 
Effect of variation in flow rate: 
 Prepare the system suitability solution as per the test method and inject into 
the HPLC system with ±0.2 ml of the method flow. Evaluate the system suitability 
values as required by the test method for both flow rates. Actual flow rate was 1.0 
ml/min and it was changed to 0.8ml/min and 1.2ml/min and inject into HPLC and 
system suitability was checked. 
Effect of variation in Temperature: 
 Prepare the system suitability solution as per the test method and injected into 
the HPLC with ±5oc of the method temperature. Evaluate the system suitability values 
as required by the test method for both temperatures. 
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10. SYSTEM SUITABILITY 
Table No: 9 System suitability data of Paracetmol and Flupirtine maleate 
Parameter Paracetmol Flupirtine 
maleate 
Acceptance 
criteria 
Retention time 4.731 3.353 
 
Theoretical plates 13958 9156 >2500 
Tailing factor 1.24 1.29 <2.00 
% RSD 0.1 0.1 <2.00 
 
Table No : 10 Standard Results of Paracetmol 
S. No. Sampl name RT Area USP plate 
count 
USP 
tailing 
Injection1 4.720 1081754 13904 1.22 
Injection 2 4.739 1089163 13901 1.23 
Injection 3 4.716 1097378 13879 1.23 
Injection 4 4.736 1084949 14257 1.23 
Injection 5 4.738 1089191 14143 1.22 
 
Table No : 11 Standard Results of Flupirtine maleate 
S.No Sample name RT Area USP plate 
count 
USP 
tailing 
1. Injection 1 3.333 928391 8453 1.27 
2. Injection 2 3.360 904815 8979 1.26 
3. Injection 3 3.342 906819 9188 1.26 
4. Injection 4 3.358 909101 9228 1.27 
5. Injection 5 3.354 907622 9298 1.27 
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Fig No: 13 typical Chromatogram of Standard 1 
 
 
Fig No: 14 typical Chromatogram of Standard-2; Injection-1 
 
Fig No: 15 typical Chromatogram of Standard-2; Injection-2 
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Fig No: 16 typical Chromatogram of Standard-2; Injection-3 
 
Fig No: 17 typical Chromatogram of Standard-2; Injection-4 
 
                 Fig No: 18 typical Chromatogram of Standard-2; Injection-5 
 
RESULT 
                    Results of system suitability study are summarized in the above table. Six 
consecutive injections of the standard solution showed uniform retention time, 
theoretical plate count, tailing factor and resolution for both the drugs which indicate 
a good system for analysis. 
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2. SPECIFICITY: 
Table no: 12 Specificity data for Paracetmol and Flupirtine maleate 
       
 
Fig no: 19 Typical chromatogram of the blank 
                                            
 
Fig no: 20 chromatogram representing specificity of standard 
 S no Sample name Paracetmol 
area 
Rt Flupirtine maleate Area Rt 
1 Standard 2251240 1.950 21020626 3.858 
2 Sample 2252365 1.944 21107354 3.838 
3 Blank - - - - 
4 Placebo - - - - 
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                    Fig no: 21 chromatogram representing specificity of sample  
RESULT 
              Chromatograms explain that retention time for standard, sample and 
commercial product of Paracetmol and Flupirtine maleate are same. This proves that, 
excipients have no effect on the analytical method. On the other hand, blank peak did 
not overlap drug peak. So the method is highly selective. 
3. ACCURACY: 
Table No: 13 Accuracy data for Paracetmol 
S.NO Accuracy level injecton Sample area RT 
 
1 
 
80% 
1 541598 4.733 
2 546689 4.726 
3 541728 4.709 
 
2 
 
100% 
1 1089965 4.728 
2 1080210 4.732 
3 1085854 4.715 
 
3 
 
120% 
1 1667553 4.755 
2 1666002 4.743 
3 1666117 4.732 
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Table no: 14 Accuracy (%recovery) results of Paracetmol 
S.NO Accuracy 
Level 
Sample 
name 
Sample 
weight 
µg/ml 
added 
µg/ml 
found 
% 
Recovery 
% 
Mean 
 
1 
 
80% 
1 401.02 321.750 322.45 100 
101 2 401.02 321.750 325.48 101 
3 401.02 321.750 322.53 100 
 
2 
 
100% 
1 802.04 643.500 648.93 101 
 
 
100 
2 802.04 643.500 643.12 100 
3 802.04 643.500 646.48 100 
 
3 
 
120% 
1 1203.06 965.250 992.81 103 
 
 
103 
2 1203.06 965.250 991.88 103 
3 1203.06 965.250 991.95 103 
 
Table no: 15 Accuracy data for Flupirtine maleate 
S.NO Accuracy 
level 
Sample 
name 
Sample area RT 
 
1 
 
80% 
1 459327 3.348 
2 456469 3.358 
3 450190 3.335 
 
2 
 
100% 
1 910952 3.345 
2 916393 3.366 
3 916445 3.337 
 
3 
 
120% 
1 1367985 3.370 
2 1364944 3.367 
3 459327 3.348 
 
  
Chapter 10 Results and Discussion 
Dept. of Pharmaceutical Analysis  67 J.K.K. Nattraja College of Pharmacy 
Table no: 16 Accuracy (%recovery) results of Flupirtine maleate 
S.NO Accuracy 
level 
Sample 
name 
Sample 
weight 
µg/ml 
added 
µg/ml 
found 
% 
Recovery 
% 
Mean 
1 80% 
1 401.02 99.000 99.89 101 
 
 
100 
2 401.02 99.000 99.27 100 
3 401.02 99.000 97.91 99 
2 100% 
1 802.04 198.000 198.11 100 
 
 
100 
2 802.04 198.000 199.30 101 
3 802.04 198.000 199.31 101 
3 120% 
1 1203.06 297.000 297.51 100 
 
 
100 
2 1203.06 297.000 296.85 100 
3 1203.06 297.000 296.15 100 
 
 
Fig no: 23 Typical chromatogram for Accuracy 80 % 
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Fig no: 24 Typical chromatogram for Accuracy 100 % 
 
 
Fig no: 25 Typical chromatogram for Accuracy 120 % 
RESULT 
             Results of accuracy study are presented in the above table. The measured 
value was obtained by recovery test. Spiked amount of both the drug were compared 
against the recovery amount. 
% Recovery was 101.00% for Paracetmol and 100.00% for Flupirtine maleate. 
All the results indicate that the method is highly accurate.     
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PRECISION: 
                 Table no: 17 Precision data for Paracetmol 
S.no RT Area %Assay 
injection1 4.739 1078871 99 
injection2 4.734 1064983 98 
injection3 4.746 1083323 99 
injection4 4.727 1080612 99 
injection5 4.725 1078487 99 
injection6 4.740 1072778 98 
Mean   99 
Std. Dev.   0.61 
% RSD   0.62 
 
                Table no: 18 Precision data for Flupirtine maleate 
S.no RT Area %Assay 
injection1 3.357 911468 99 
injection 2 3.356 910692 99 
injection  3 3.365 913771 99 
injection  4 3.354 914557 99 
injection  5 3.342 910623 99 
injection  6 3.359 910986 99 
Mean   99 
Std. Dev.   0.19 
%RSD   0.19 
 
 
Fig no: 26 Chromatogram for precision injection 1 
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                        Fig no: 27 Chromatogram for precision injection  
 
 
Fig no: 28 Chromatogram for precision injection 3 
 
 
Fig no: 29 Chromatogram for precision injection 4 
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Fig no: 30 Chromatogram for precision injection 5 
 
Fig no: 31 Chromatogram for precision injection 6 
RESULT 
Results of variability were summarized in the above table. % RSD of peak 
areas was calculated for various run. Percentage relative standard deviation (%RSD) 
was found to be less than 2% which proves that method is precise. 
  
Chapter 10 Results and Discussion 
Dept. of Pharmaceutical Analysis  72 J.K.K. Nattraja College of Pharmacy 
 5. LINEARITY: 
Table no: 19 Linearity data for Paracetmol 
 
S.no Conc(µg/ml) RT Area 
1. 50 4.741 545934 
2. 75 4.745 545471 
3. 100 4.738 1089953 
4. 125 4.733 1363163 
5. 150 4.729 1646171 
 
 
 
Fig no: 32 Linearity plot of Paracetmol 
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Table no: 20 Linearity data for Flupirtine maleate 
s.no Conc(µg/ml) RT Area 
1. 50 3.362 452965 
2. 75 3.359 681710 
3. 100 3.359 917312 
4. 125 3.357 1145499 
5. 150 3.356 1362576 
 
 
 
Fig no: 33 Linearity plot of Flupirtine maleate  
 
                        Fig no: 34 Chromatogram representing lineartity 1 
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Fig no: 35 Chromatogram representing linearity 2 
Fig no: 36 Chromatogram representing linearity 3 
 
Fig no: 37 Chromatogram representing linearity 4 
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                                  Fig no: 38 Chromatogram representing linearity 5 
RESULT 
A linear relationship between peak areas versus concentrations was observed 
for Paracetmol and Flupirtine maleate in the range of 50% to 150% of nominal 
concentration. Correlation coefficient was 0.999 for both Paracetmol and Flupirtine 
maleate which prove that the method is linear in the range of 50% to 150%. 
6. ROBUSTNESS:  
Table no: 21 Robustness data for Paracetmol 
parameter RT Theoretical 
plates 
Asymmetry 
Decreased flow rate(0.6ml/min) 5.270 14731 1.27 
Increased flow rate(1.0ml/min) 4.321 13704 1.21 
Decreased temperature(200c) 5.237 13997 1.25 
Increased temperature(300c) 4.310 13146 1.22 
                     
Table no: 22 Robustness data for Flupirtine maleate 
parameter RT Theoretical 
plates 
Asymmetry 
Decreased flow rate(0.6ml/min) 3.726 9384 1.31 
Increased flow rate(1.0ml/min) 3.050 8891 1.26 
Decreased temperature(200c) 3.710 9499 1.31 
Increased temperature(300c) 3.049 9005 1.26 
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Fig no: 39 Chromatogram for decreased flow rate 
 
Fig no: 40 Chromatogram for increased flow rate 
 
Fig no: 41 Chromatogram for decreased temperature 
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Fig no: 42 Chromatogram for increased temperature 
RESULT 
               The results of Robustness of the present method had shown that changes 
made in the Flow and Temperature did not produce significant changes in analytical 
results which were presented in the above table. As the changes are not significant we 
can say that the method is Robust. 
7. LIMIT OF DETCTION: 
Minimum concentration of standard component in which the peak of the 
standard gets merged with noise called the LOD 
LOD = 3.3* σ/S 
Where; 
σ  = standard deviation 
S = slope 
LOD for Paracetmol = 3.769700 
 LOD for Flupirtine maleate = 3.182503 
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Fig no: 43 Chromatogram for LOD 
8. LIMIT OF QUANTIFICATION: 
Minimum concentration of standard component in which the peak of the 
standard gets detected and quantification 
LOQ = 10*σ/S 
Where; 
σ  = standard deviation 
S = slope 
LOQ for Paracetmol = 10.136540 
  LOQ for Flupirtine maleate = 10.259800 
 
Fig no: 44 Chromatogram for LOQ
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11. CONCLUSION 
The study is focused to develop and validate HPLC methods for estimation of 
Paracetmol and  Flupirtine  male ate  in  tablet dosage form. 
For routine analytical purpose it is desirable to establish methods capable of 
analyzing huge number of samples in a short time period with good robustness, 
accuracy and precision without any prior separation steps. HPLC method generates 
large amount of quality data, which serve as highly powerful and convenient 
analytical tool. 
 The method shows good reproducibility and good recovery. From the 
specificity studies, it was found that the developed methods were specific for 
Paracetmol  and  Flupirtine  maleate.  Al l the  parameters  of  the  methods. 
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12. SUMMARY OF PARACETMOL 
Table no: 23 Summary of validation data for Paracetmol 
S.NO PARAMETER RESULT ACCEPTENCE 
CRITERIA 
1 System suitability 
Theoretical plates 
Asymmetry 
Retention time 
%RSD 
 
13958 
1.24 
4.731 
0.1 
 
Not less than 2500 
Not more than2 
 
 
2 Specificity 
a) Blank interference 
b) Placebo 
interference 
 
 
Specific 
 
 
Specific 
3 Method precision(%RSD) 0.62 Not more than 2.0% 
4 Linearity parameter 
Slope 
Correlation coefficient(r2) 
50-150 mcg/ml 
43363 
0.999 
 
Not less than 0.999 
5 Accuracy 
Mean % recovery 
 
101.00 
 
97 - 103% 
6 Robustness 
a) Flow rate 
variation 
b) Temperature 
variation 
All the system 
suitability 
parameters are 
within the 
limits. 
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SUMMARY OF FLUPIRTINE MALEATE: 
Table no: 24 Summary of validation data for Flupirtine maleate 
S.NO PARAMETER RESULT ACCEPTENCE CRITERIA 
1 System suitability 
Theoretical plates 
Asymmetry 
Retention time 
%RSD 
 
9156 
1.29 
3.353 
0.1 
 
Not less than 2500 
Not more than 2 
 
 
2 Specificity 
c) Blank interference 
d) Placebo interference 
 
 
Specific 
 
 
Specific 
3 Method precision(%RSD) 0.19 Not more than 2.0% 
4 Linearity parameter 
Slope 
Correlation coefficient(r2) 
50-150 mcg/ml 
10569 
0.999 
 
Not less than 0.999 
5 Accuracy 
Mean % recovery 
 
100.00 
 
97 - 103% 
6 Robustness 
c) Flow rate variation 
d) Temperature 
variation 
All the system 
suitability 
parameters are 
within the 
limits. 
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